This study demonstrated, (i) the importance of Nectin-4 as a biological target for bladder cancer, relative to PD-L1, and (ii) EV has the potential to significantly extend the lives of patients, including those who failed ICI treatment. The gene discussed is NECTIN4; the disease is urinary bladder cancer.